Advaxis names Christopher Duke SVP and COO
Mr. Duke, a biotech veteran with more than 20 years of life sciences experience, will lead operations at Advaxis with a focus on overseeing the company’s clinical development programs as well as managing early commercial planning activities.
Most recently, Mr. Duke served as Vice President, Global Commercial Operations at Amicus Therapeutics, Inc. where he played a lead role in the build out of the international business to support the successful launch of Galafold (migalastat).
As one of the first employees at Amicus, he held numerous leadership roles in program/alliance management, medical affairs and commercial planning over 10 years for multiple products across all stages of development.
In addition, Mr. Duke previously served as Executive Director, International Commercial Operations for NPS Pharma where he led several strategic business planning initiatives and helped to establish NPS International to support the ex-US commercialization of Revestive (teduglutide) and Natpar.
Mr. Duke received his MBA from the Wharton School, University of Pennsylvania, his MPH from the University of Medicine and Dentistry of New Jersey and a Bachelor of Science in chemical engineering from Rutgers University.
With the addition of Mr. Duke, Executive Vice President Greg Mayes will step into the role of Chief Business Officer where he will continue to expand the company’s focus on identifying and executing on licensing, development, and collaboration opportunities for Advaxis’ Lm Technology.
Mr. Mayes will also oversee corporate strategy and lead the re-initiation of a company focus on leveraging the Advaxis technology for infectious disease programs. ■
What to read next